HU6 - The most advanced mitochondrial uncoupler

frenexen

Member
I'm creating this to hopefully bring light to HU6 so we can see it enter the UGL scene as soon as possible. TLDR; BAM15 not good, HU6 good.

Currently, the most promising mitochondrial uncoupler in the market seems to be BAM15. BAM15 shows high selectivity in the liver and adipose tissue, but it has never been tested in humans, has a seemingly short half life in mice, and is often taken at completely inefficient doses.

Just by using equivalent doses from rodent studies we'd need at least 1g per day before it really starts to have a roughly 10% increase in RMR. But it may get even worse. The mouse liver is roughly 12x more metabolically active than the human liver, so it would be expected that BAM15, which is liver selective, is more effective in mice. But, because of this, it's also likely that BAM15 has a far longer half-life in humans, maybe 10x as much or more. Unfortunately, we have no determination on this, and we don't know the actual bioavailability in humans. From personal anecdote, I can say I was noticeably still hotter after an acute 5g dose roughly 16-20 hours later, where otherwise I haven't noticed any increase in sweating from an acute 2g dose. So I would think at least the half-life is considerably longer. Not saying this dose is needed at all, I was simply using it to test if it was actually working and half-life hypothesis, as normal likely effective doses would not cause hyperthermia.

All of that to say, we really don't have any idea how much is needed. Because of this uncertainly, it's dosed randomly in the UGL. I can say for certain your 50mg tablets aren't doing shit- it's not even close to what is needed.

HU6 is a drug slated to enter phase 3 trials for multiple metabolic conditions. It is simply a prodrug to DNP, practically eliminating systemic effects by concentrating the effects at the liver in therapeutic doses. DNP is so dangerous because it is active in virtually all tissue, which is why you sweat it out, why it likely causes cataracts through metabolic disruption, and has no therapeutic ceiling.

HU6 is tested in humans and presents a similar side effect burden to BAM15. Studies noted no increase in body temperature, with the most common side effect being flushing (30% vs. 10% in placebo). HU6, like any other uncoupler is great for diabetes, NAFLD, visceral fat, preservation of lean mass, etc.

Doses in humans (once daily) and corresponding TDEE increases are estimated to be the following:
150mg > +10%
300mg > +20%
450mg > +30%

Personally, I doubt it actually scales so linearly because of its selectivity and this is just an estimate the researchers came to. The real question is at what dose do the effects become systemic so we can avoid it; that is unexplored.

More details on study results: https://www.rivuspharma.com/wp-content/uploads/2023/10/Rivus_LancetGE_Publication_PR.pdf

So not only does HU6 not require massive doses, but it also doesn't require fats for absorption either like BAM15.

The chemical structure would also imply that it's probably not that complicated to synthesize either, but I'll leave that to smarter minds than me.

Hopefully we see in the UGL soon, or maybe even coordinate a custom raw synthesis group buy if the price is right. In any case, please stop wasting money on microdoses of BAM15 (and SLU, shit is dumb af.)
 
Hopefully we see in the UGL soon, or maybe even coordinate a custom raw synthesis group buy if the price is right. In any case, please stop wasting money on microdoses of BAM15 (and SLU, shit is dumb af.)

The issue with these compounds is cost, anything new is expensive, very expensive.
That's why BAM15 is dosed so low, and also why there are some GLPs who aren't talked about or used much, because the cost makes it prohibitive.
 
The issue with these compounds is cost, anything new is expensive, very expensive.
That's why BAM15 is dosed so low, and also why there are some GLPs who aren't talked about or used much, because the cost makes it prohibitive.
For sure, but if the customers don't know what dose is required, and the 50mg tablets are selling, there is no incentive to upscale production.

Small molecules aren't as complicated as peptides in this regard. A large company could easily make kgs at one time so long as they have the equipment.

Slu for example is far cheaper than BAM15 now due to its popularity. Yet its still selling in mcg doses in most places. Neither of these drugs are working in the doses they are being used, and anyone at least slightly resistant to placebo knows this. We don't even have a single study on slu that even used oral doses, and it's selling like hot cakes at 1000x less than would theoretically be needed from HED adjustments.

We should promote the production of drugs that actually work and have results, and price reductions will quickly follow.
 
For sure, but if the customers don't know what dose is required, and the 50mg tablets are selling, there is no incentive to upscale production.

You can also argue it the other way. Products are not selling, there is no demand and no reason to upscale production. Why produce more of a product that's not selling? There needs to be demand (low dosed or whatever) before production is scaled up.

Slu for example is far cheaper than BAM15 now due to its popularity. Yet its still selling in mcg doses in most places. Neither of these drugs are working in the doses they are being used, and anyone at least slightly resistant to placebo knows this. We don't even have a single study on slu that even used oral doses, and it's selling like hot cakes at 1000x less than would theoretically be needed from HED adjustments.

Prices of SLU have dropped significantly due to popularity.
5g of raws was $110 in Feb. its now $160 for 20g.
There are now vendors selling 20mg SLU, in Feburary this was not even available. (I don't use SLU). Prices of everything popular (except AAS) has mostly dropped throughout the year. Those not popular have not budged much.
 
You can also argue it the other way. Products are not selling, there is no demand and no reason to upscale production. Why produce more of a product that's not selling? There needs to be demand (low dosed or whatever) before production is scaled up
Correct, and if a customer buys a drug with no clinical evidence and notices nothing are they likely to demand higher doses or stop using it entirely? I’d bet the latter is more likely.


Prices of SLU have dropped significantly due to popularity.
5g of raws was $110 in Feb. its now $160 for 20g.
Yep, and if there was proven clinical evidence that 500mg or something was required as a minimum effective dose in humans I’d bet it would have dropped even faster. Hypothetical, of course, as I believe it has virtually zero oral bioavailability.
 
Bam15 seems to be a complete failure. I've yet to see a report of major weight loss. From your description this new drug sounds promising but until it's available and affordable DNP works great for uncoupling and weight loss. It's also dirt cheap.
 
You can also argue it the other way. Products are not selling, there is no demand and no reason to upscale production. Why produce more of a product that's not selling? There needs to be demand (low dosed or whatever) before production is scaled up.



Prices of SLU have dropped significantly due to popularity.
5g of raws was $110 in Feb. its now $160 for 20g.
There are now vendors selling 20mg SLU, in Feburary this was not even available. (I don't use SLU). Prices of everything popular (except AAS) has mostly dropped throughout the year. Those not popular have not budged much.

i tried to DM you about finding slu for this price but you dont take private messages :'> I havent found 10g for under $160.
 
I always would be careful when a study is financed and run by the same company who develops the drug, the way i read it is a bit "too good to be true" plus when its just a prodrug i'd be even more careful but interesting for sure!
 
I always would be careful when a study is financed and run by the same company who develops the drug, the way i read it is a bit "too good to be true" plus when its just a prodrug i'd be even more careful but interesting for sure!
Yeah, though that is pretty much everything now. There is no incentive to run studies on patented drugs when you aren’t the patent holder.

And that is where my speculation is, on their estimate of RMR increase. It wasn’t directly measured, and the results of phase 2 studies show that 300mg was similar to 450mg; in fact 450mg was slightly worse.

BAM15 shows a dose ceiling and large safety range, so if HU6 is more selective it should be the same outcome, and it was based on their own data on weight loss and visceral fat loss.

HU6 will never compete with DNP, nothing will. You can’t have the selectivity and potency at the same time; the liver can only handle so much.

I see HU6 as an adjunct to other therapies when used for weight loss, mainly the incretin drugs.
But it also serves another huge purpose as an insulin sensitizing agent. Uncouplers are extremely potent at this, and HU6 is no different from its results on visceral fat. With its safety profile it could be run year round low dose for just this purpose and blow metformin out of the water as first line therapy.
 

Sponsors

Back
Top